RU2015125343A - Гуманизированные моноклональные антитела против активированного белка с и их применение - Google Patents

Гуманизированные моноклональные антитела против активированного белка с и их применение Download PDF

Info

Publication number
RU2015125343A
RU2015125343A RU2015125343A RU2015125343A RU2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A RU 2015125343 A RU2015125343 A RU 2015125343A
Authority
RU
Russia
Prior art keywords
antibody
seq
cell
residue
subject
Prior art date
Application number
RU2015125343A
Other languages
English (en)
Russian (ru)
Inventor
Ксиао-ян ЖАО
Жуожи ВАНГ
Йи-Юн КИМ
Йинг ЖУ
Ян Теббе
Original Assignee
БАЙЕР ХелсКер ЛЛСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БАЙЕР ХелсКер ЛЛСи filed Critical БАЙЕР ХелсКер ЛЛСи
Publication of RU2015125343A publication Critical patent/RU2015125343A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2015125343A 2012-11-29 2013-11-27 Гуманизированные моноклональные антитела против активированного белка с и их применение RU2015125343A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731368P 2012-11-29 2012-11-29
US61/731,368 2012-11-29
PCT/US2013/072137 WO2014085527A1 (en) 2012-11-29 2013-11-27 Humanized monoclonal antibodies against activated protein c and uses thereof

Publications (1)

Publication Number Publication Date
RU2015125343A true RU2015125343A (ru) 2017-01-11

Family

ID=50828440

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015125343A RU2015125343A (ru) 2012-11-29 2013-11-27 Гуманизированные моноклональные антитела против активированного белка с и их применение

Country Status (17)

Country Link
US (2) USRE49099E1 (enExample)
EP (1) EP2925360A4 (enExample)
JP (1) JP2016501875A (enExample)
KR (1) KR20150088853A (enExample)
CN (1) CN104936618A (enExample)
AR (1) AR093672A1 (enExample)
AU (1) AU2013352260A1 (enExample)
BR (1) BR112015012458A2 (enExample)
CA (1) CA2892748A1 (enExample)
HK (1) HK1215174A1 (enExample)
IL (1) IL238920A0 (enExample)
MX (1) MX2015006738A (enExample)
RU (1) RU2015125343A (enExample)
SG (1) SG11201504035PA (enExample)
TW (1) TW201437229A (enExample)
UY (1) UY35160A (enExample)
WO (1) WO2014085527A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) * 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2020051277A1 (en) 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
KR20240152428A (ko) * 2022-03-04 2024-10-21 주식회사 코애귤런트테라퓨틱스 활성화된 단백질 c에 대한 인간 항체 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5279956A (en) 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
DE60141844D1 (de) 2000-10-02 2010-05-27 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US20030203355A1 (en) 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
SI3219328T1 (sl) * 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
NZ574804A (en) 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
BRPI0818865A2 (pt) 2007-10-26 2015-05-05 Oklahoma Med Res Found Anticorpos monoclonais contra proteína c ativada.
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof

Also Published As

Publication number Publication date
EP2925360A1 (en) 2015-10-07
US20150322164A1 (en) 2015-11-12
KR20150088853A (ko) 2015-08-03
WO2014085527A1 (en) 2014-06-05
US9657111B2 (en) 2017-05-23
CA2892748A1 (en) 2014-06-05
EP2925360A4 (en) 2016-07-13
AR093672A1 (es) 2015-06-17
MX2015006738A (es) 2015-08-05
JP2016501875A (ja) 2016-01-21
HK1215174A1 (zh) 2016-08-19
TW201437229A (zh) 2014-10-01
SG11201504035PA (en) 2015-06-29
IL238920A0 (en) 2015-07-30
AU2013352260A1 (en) 2015-06-11
UY35160A (es) 2014-06-30
BR112015012458A2 (pt) 2018-02-06
CN104936618A (zh) 2015-09-23
USRE49099E1 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
RU2760875C1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
AU2017237543B2 (en) Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
RU2462475C2 (ru) Антитела против вируса гепатита с
CN103864924B (zh) 一种中东呼吸综合征冠状病毒抗体及其制备方法
AR134583A2 (es) Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
RU2019118359A (ru) Антитело к cd73 человека
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
RU2019119862A (ru) Антитела к компоненту комплемента c5
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
RU2017123549A (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
CA2777691A1 (en) Monoclonal antibodies to progastrin and their uses
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
RU2016123839A (ru) Новые модуляторы и способы их применения
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
RU2016137256A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
WO2014106235A1 (en) Anti-granulysin antibodies and methods of use thereof
JP2019501139A5 (enExample)
RU2017145094A (ru) Нейтрализующие связывающие молекулы, направленные против вируса гриппа, и пути их применения
JP2016530223A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20161128